4-(1-cyclopropylpiperidin-4-yl)benzoic acid | 1001547-97-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1-cyclopropylpiperidin-4-yl)benzoic acid
• CAS: 1001547-97-2
• 化学式: C₁₅H₁₉NO₂
• 分子量: 245.321
• InChiKey: LJOHNDTVZFXRKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 4-(1-cyclopropylpiperidin-4-yl)benzoate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 水 为溶剂， 反应 4.0h， 生成 4-(1-cyclopropylpiperidin-4-yl)benzoic acid
  参考文献：
  名称：

  WO2008/7130

  摘要：

  公开号：

文献信息

• Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors
  申请人：Quibell Martin

  公开号：US20100010009A1

  公开（公告）日：2010-01-14

  The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R 1 and R 2 is H, and the other is selected from F and Cl, or R 1 and R 2 are both F; R 3 is selected from cyclopentyl and cyclohexyl; R 4 is an optionally substituted 5- or 6-membered monocyclic or an 8- to 10-membered bicyclic aryl or heteroaryl ring which includes up to four heteroatoms. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（1）的化合物及其药学上可接受的盐，式（I）的化合物或药学上可接受的盐、水合物、配合物或前药，其中：R1和R2中的一个为H，另一个为F和Cl中的一种，或R1和R2均为F；R3选自环戊基和环己基；R4为可选取代的5-或6-成员单环或8-到10-成员的双环芳基或杂环芳基环，其中包含最多四个杂原子。本发明还涉及包括式（I）的化合物的制药组合物，并且在治疗骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛中使用这种化合物的用途。
• FURO[3. 2-B] PYRROL DERIVATIVES
  申请人：Quibell Martin

  公开号：US20100216811A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R 3 is tert-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R 4 is optionally substituted C 1-8 alkyl or optionally substituted C 3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中：R3是叔丁基甲基、仲丁基或叔丁基；X是CH或N；R4是可选取代的C1-8烷基或可选取代的C3-8环烷基。本发明还涉及包含式（I）的化合物的药物组合物，以及将这些化合物用于治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病，以及骨癌疾病，如骨转移和相关疼痛。
• Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
  申请人：Quibell Martin

  公开号：US20090203714A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; and R 4 is optionally substituted C 3-8 alkyl or optionally substituted C 3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中：X为CH或N；R4为可选取的取代的C3-8烷基或可选取的取代的C3-8环烷基。本发明还涉及包含式（I）化合物的制药组合物，以及在治疗从骨质疏松症、帕盖特病、查加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌症状如骨转移和相关疼痛中使用这些化合物的用途。
• Furo[3, 2-b] pyrrol derivatives
  申请人：Quibell Martin

  公开号：US20090186906A1

  公开（公告）日：2009-07-23

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R 3 is ten-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R 4 is optionally substituted C 1-8 alkyl or optionally substituted C 3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中：R3是十丁基甲基、仲丁基或叔丁基；X是CH或N；R4是可选取代的C1-8烷基或可选取代的C3-8环烷基。本发明还涉及包含式（I）的化合物的制药组合物，以及在治疗骨质疏松症、帕盖特病、恰加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌性疾病如骨转移和相关疼痛方面使用这些化合物的用途。
• Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors
  申请人：Quibell Martin

  公开号：US20090197817A1

  公开（公告）日：2009-08-06

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: X is CH or N; one of R 1 and R 2 is H, and the other is selected from OR 6 , SR 6 , NR 6 R 7 , N 3 , Me, Et, CF 3 , SOR 8 and SO 2 R 8 ; R 3 is selected from tert-butylmethyl, iso-propylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R 4 is optionally substituted C 1-8 alkyl or optionally substituted C 3-8 cycloalkyl; R 6 and R 7 are each independently selected from H, C 1-8 -alkyl and C 3-8 -cycloalkyl, or R 6 and R 7 are linked to form a cyclic group together with the nitrogen to which they are attached; and R 8 is C 1-8 -alkyl or C 3-8 -cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中：X为CH或N；R1和R2中的一个为H，另一个选自OR6、SR6、NR6R7、N3、Me、Et、CF3、SOR8和SO2R8；R3选自叔丁基甲基、异丙基甲基、仲丁基、叔丁基、环戊基和环己基；R4为可选取代的C1-8烷基或可选取代的C3-8环烷基；R6和R7各自独立选自H、C1-8烷基和C3-8环烷基，或者R6和R7与它们所连接的氮一起形成一个环状基团；R8为C1-8烷基或C3-8环烷基。本发明还涉及包含式（I）化合物的药物组合物，以及在治疗骨质疏松症、帕盖特病、恰加斯病、疟疾、牙龈疾病、高钙血症、代谢性骨病、涉及基质或软骨降解的疾病以及骨癌疾病如骨转移和相关疼痛方面使用这种化合物的方法。